Quest Diagnostics Extends Colorectal Screening Reach With Guardant Shield Partnership

Quest Diagnostics (NYSE:DGX) is partnering with Guardant Health to offer Shield, an FDA-approved blood test for colorectal cancer screening, across its nationwide network. The agreement expands access ...
Nasdaq

Mainz Biomed Enters Agreement with Quest Diagnostics to Advance ColoAlert Colorectal Cancer Screening Test

Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to commercialize its stool-based colorectal cancer screening test, ColoAlert, which detects tumor DNA to identify early-stage ...

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through ...
Medical News Today

What to know about a stool test

A stool test is a diagnostic procedure that involves analyzing fecal matter, or poop, to check for signs of infection, inflammation, or disease. The specific analysis depends on a person’s symptoms ...